AI assistant
ATOMO DIAGNOSTICS LIMITED — Call Transcript 2021
Aug 26, 2021
64440_rns_2021-08-26_d9bb6309-d70c-4389-97b0-ce091a5146ed.pdf
Call Transcript
Open in viewerOpens in your device viewer
ASX Announcement
==> picture [181 x 52] intentionally omitted <==
27 August 2021
Atomo FY21 results investor briefing
SYDNEY Australia Friday, 27 August 2021: Atomo Diagnostics Limited (ASX: AT1) is pleased to invite investors to attend an online briefing to discuss its financial results for the year ended 30 June 2021 (FY21).
The online briefing will be held on Monday, 30 August 2021 at 2.30pm (Sydney time) .
During the briefing, Managing Director and CEO, John Kelly and CFO, Will Souter will present an activity update. This will be followed by a Q+A session.
Participants will need to pre-register ahead of time, via the following link:
https://us02web.zoom.us/webinar/register/WN_xp5x0SdjQP2ToylcRAhb2g
Once the registration form is completed, investors will receive a confirmation email with detail on how to access the briefing. If you would like to ask a question during the briefing, please send it ahead of the session to: [email protected]
For more information, please contact:
Jane Lowe John Kelly IR Department Atomo Diagnostics [email protected] [email protected] Phone: +61 411 117 774 Phone: +61 401 922 279
This announcement was authorised by John Kelly, Managing Director.
About Atomo
Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. Atomo has supply agreements in place for tests targeting a range of infectious diseases including for HIV, COVID-19, and viral vs bacterial differentiation.
See more at www.atomodiagnostics.com.